EyePoint Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
EYPT
CUSIP
30233G209
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 30233G209 since 12/18/2024, newest first.

Filer % of Class Filed
Federated Hermes, Inc. 13G/A Amendment 2
8.0% 10/7/2026
Event 9/30/2026
Janus Henderson Group Ltd. 13G 10.9% 9/8/2026
Event 8/31/2026
Cormorant Asset Management, LP 13G/A Amendment 4
8.4% 8/14/2026
Event 6/30/2026
Adage Capital Management, L.P. 13G
5.7% 8/12/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.0% 7/31/2026
Event 6/30/2026
BlackRock, Inc. 13G/A Amendment 2 7.7% 7/28/2026
Event 6/30/2026
Commodore Capital LP 13G
5.1% 6/3/2026
Event 5/27/2026
Paradigm Biocapital Advisors LP 13G/A Amendment 1
3.8% 5/15/2026
Event 3/31/2026
Adage Capital Management, L.P. 13G/A Amendment 7
4.0% 5/13/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 2 0% 3/26/2026
Event 3/13/2026
Paradigm Biocapital Advisors LP 13G
5.1% 2/24/2026
Event 2/17/2026
TCG Crossover GP II, LLC 13G/A Amendment 1
4.3% 2/17/2026
Event 12/31/2025
Adage Capital Management, L.P. 13G/A Amendment 6
5.7% 2/12/2026
Event 12/31/2025
Cormorant Asset Management, LP 13G/A Amendment 3
10.0% 12/8/2025
Event 12/4/2025
Adage Capital Management, L.P. 13G/A Amendment 5
8.1% 11/13/2025
Event 9/30/2025
BlackRock, Inc. 13G/A Amendment 1 6.5% 10/17/2025
Event 9/30/2025
Adage Capital Management, L.P. 13G/A Amendment 4
9.9% 8/12/2025
Event 6/30/2025
Federated Hermes, Inc. 13G/A Amendment 1
6.7% 7/8/2025
Event 6/30/2025
RA Capital Management, L.P. 13G/A Amendment 3
4.7% 2/14/2025
Event 12/31/2024
Adage Capital Management, L.P. 13G/A Amendment 3
8.4% 2/12/2025
Event 12/31/2024
Franklin Resources, Inc. 13G/A Amendment 7
6.1% 1/27/2025
Event 12/31/2024
Franklin Resources, Inc. 13G/A Amendment 6
7.5% 10/31/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 4.21 k $13.8 k
2026 Q2 209 94.3 M $1.43 B
2026 Q1 206 90.1 M $1.16 B
2025 Q4 178 83.6 M $1.53 B
2025 Q3 164 69.9 M $996 M
2025 Q2 154 69.1 M $651 M
2025 Q1 162 74.1 M $402 M
2024 Q4 154 74.4 M $553 M
2024 Q3 148 58.9 M $479 M
2024 Q2 167 61.0 M $531 M
2024 Q1 182 58.0 M $1.20 B
2023 Q4 163 52.1 M $1.20 B
2023 Q3 111 33.7 M $270 M
2023 Q2 88 31.6 M $275 M
2023 Q1 71 29.1 M $85.6 M
2022 Q4 82 29.8 M $104 M
2022 Q3 92 31.5 M $250 M
2022 Q2 88 30.2 M $238 M
2022 Q1 89 30.4 M $370 M
2021 Q4 99 29.8 M $365 M
2021 Q3 70 22.1 M $231 M
2021 Q2 68 20.7 M $186 M
2021 Q1 67 19.6 M $200 M
2020 Q4 35 7.70 M $50.7 M